Clinical trials: Streptococcus Pneumoniae Vaccines
Pneumonia, Pneumococcal
Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants
The primary objectives of this study are to evaluate the immunogenicity (antibody response) and safety and tolerability of a 2-dose primary series and booster dose (2+1 schedule) of Pneumosil co-administered with routine…
- Trial name
- NCT03896477
- Testing
- Pneumosil, Prevenar 13, Synflorix
- Where
- The Gambia
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- PATH
HIV Infections
Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects
The purpose of this study is to evaluate the best timing for administering pneumococcal vaccine (PV) to HIV-infected adults that have CD4 cell counts of more than 200 and are not yet receiving combination antiretroviral treatment…
- Trial name
- NCT00706550
- Testing
- (PV) 23-valent pneumococcal polysaccharide vaccine
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- US Department of Veterans Affairs
Vaccines, Pneumococcal Conjugate Vaccine
Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
People who have received an allogeneic hematopoetic stem cell transplant (HSCT) are more likely than other people to get ill from a germ called Streptococcus pneumoniae.
- Trial name
- NCT00980655
- Testing
- 13vPnC, 23vPS
- Where
- 47 sites in United States, Belgium and 8 more
- Volunteers
- 251 people
- Sponsor
- Pfizer
Pneumococcal Disease
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and…
- Trial name
- NCT07629440
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 130 sites in United States, Japan and 1 more
- Volunteers
- 3,230 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
- Trial name
- NCT04530838
- Testing
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- 38 sites in Japan
- Volunteers
- 668 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infectious Disease
PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months
The Phase II clinical trial of the 24-valent pneumococcal polysaccharide conjugate vaccine (RZ700) will be carried out in infants and young children aged 2 months (minimum 6 weeks) to 71 months.
- Trial name
- NCT07333352
- Testing
- 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700), 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13)
- Where
- 7 sites in China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
Relapsing Forms of Multiple Sclerosis
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
Primary objective is to evaluate the immune response to vaccination with tetanus diphtheria toxoids vaccine (Td) in participants with relapsing forms of Multiple Sclerosis (MS) who have been treated with Tecfidera (BG00012)…
- Trial name
- NCT02097849
- Testing
- dimethyl fumarate, tetanus diphtheria toxoids vaccine, 23-valent pneumococcal polysaccharide vaccine
- Where
- 14 sites in United States
- Volunteers
- 71 people
- Sponsor
- Biogen
Infections, Streptococcal
Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A
The purpose of this trial is to assess if the rate of febrile reactions following the co-administration of a booster dose of pneumococcal conjugate vaccines with standard infant vaccines is lowered when paracetamol is given…
- Trial name
- NCT00496015
- Testing
- Pneumococcal conjugate vaccine GSK1024850A., Infanrix hexa., Meningococcal vaccine GSK134612.
- Where
- 10 sites in Czechia
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Streptococcus Pneumoniae Pneumonia
PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
In the treatment of pneumococcal diseases, the common use of penicillin-based antimicrobial agents has led to drug resistance, which has become a global challenge. Therefore, disease prevention through vaccination is essential.
- Trial name
- NCT07025876
- Testing
- low dose PCV24, high dose PCV24, PPV23
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Infections, Streptococcal
Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.
The purposes of this study: To evaluate the immunogenicity, safety and reactogenicity of pneumococcal vaccine GSK1024850A in HIV infected infants, HIV exposed uninfected infants and HIV unexposed uninfected infants following a…
- Trial name
- NCT00829010
- Testing
- Pneumococcal vaccine GSK1024850A, Tritanrix-HepB/Hib, measles
- Where
- South Africa
- Volunteers
- 489 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)
The purpose of the study is to see if an investigational vaccine for Streptococcus pneumonia disease (V114) has comparable safety, tolerability, and antibody response to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX® 23) and…
- Trial name
- NCT01513551
- Testing
- Pneumococcal Conjugate Vaccine (V114), PNEUMOVAX® 23, PREVNAR 13®
- Volunteers
- 692 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Disease
Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults
The purpose of this study is to examine the safety, reactogenicity and immunogenicity of the GlaxoSmithKline (GSK) Biologicals candidate pneumococcal vaccine containing PhtD in healthy elderly population aged 18-45 years of age.
- Trial name
- NCT01767402
- Testing
- PhtD vaccine with/without adjuvant, Pneumovax 23TM, NaCl
- Where
- Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sickle Cell Disease
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV…
- Trial name
- NCT07247188
- Testing
- PCV21, 20vPCV
- Where
- 7 sites in United States, Dominican Republic
- Volunteers
- 100 people
- Sponsor
- Sanofi
Pneumococcal Vaccines
Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
Phase 2 trial to evaluate safety, tolerability, and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25)
- Trial name
- NCT06077656
- Testing
- IVT PCV-25 Formulation A, IVT PCV-25 Formulation B, IVT PCV-25 Formulation C
- Where
- 4 sites in Canada
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Inventprise Inc.
Infections, Meningococcal
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with…
- Trial name
- NCT03621670
- Testing
- Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 1,196 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia, Influenza, Human
The Effect of Live Attenuated Inactivated Influenza Vaccine on Experimental Human Pneumococcal Carriage Study
The investigators are interested in examining the effect of the Live Attenuated Influenza (flu) Vaccine (LAIV) upon nasal carriage of bacteria called Streptococcus pneumoniae (also known as pneumococcus).
- Trial name
- LAIV/EHPC (NCT03502291)
- Testing
- Study one: LAIV + Inoculation, Study two: Inoculation + LAIV
- Where
- United Kingdom
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
Pneumococcal Infections, Streptococcus Pneumoniae
Immunogenicity of PCV-7 Vaccine in VLBW Infants
Premature infants are at a high risk for pneumonia. The PCV-7 vaccine effectively prevents the invasive disease from Streptococcus pneumoniae in full-term infants, but was not thoroughly studied in premature infants.
- Conditions
- Pneumococcal Infections, Streptococcus Pneumoniae, Infant, Newborn, Infant, Low Birth Weight
- Trial name
- PCV-7 (NCT00273325)
- Where
- 10 sites in United States
- Volunteers
- 368 people, healthy volunteers welcome
- Sponsor
- NICHD Neonatal Research Network
S. Pneumoniae, Pneumococcal Conjugate Vaccine
Paediatric Post Pneumococcal Conjugate Vaccine Nasopharyngeal Carriage Study
The investigators intend to investigate the carriage of pneumococci and other respiratory microbes since the introduction of pneumococcal conjugate vaccines (Prevenar 7 and Prevenar 13).
- Trial name
- NCT04401488
- Testing
- Prevenar 7 and Prevenar 13
- Where
- United Kingdom
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (384 subjects): 1st dose : combined vaccination of COVAX+IIV4, 2nd dose: combined vaccination of COVAX+PPV23; Control Group A (384 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, Covid19
- Trial name
- NCT04790851
- Testing
- COVAX+IIV4; COVAX+PPV23, COVAX only (1st and 2nd dose), IIV4 for the 1st dose and PPV23 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,133 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Pneumococcal Infections
Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly
The purpose of this study is to evaluate the immunogenicity and safety of an investigational 23-valent pneumococcal polysaccharide vaccine (PPV) in healthy children, adults and elderly.
- Trial name
- NCT02451969
- Testing
- investigational 23-valent PPV, control 23-valent PPV
- Where
- China
- Volunteers
- 1,760 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd